Peptide Evidence Level Checker
Compare the strength of human, investigational, and preclinical evidence behind peptide compounds.
Tier 1: FDA-Approved Human Phase 3 RCTs
Supported by multi-center, double-blind, randomized controlled trials in thousands of human subjects (n > 1,000) demonstrating statistical efficacy and quantifiable safety profiles.
Semaglutide
Evidence
SUSTAIN 1-10, STEP 1-8, SELECT (n > 25,000)
Finding
14.9% mean weight loss; 20% MACE CVD risk reduction
Tirzepatide
Evidence
SURPASS 1-6, SURMOUNT 1-4 (n > 15,000)
Finding
20.9% mean weight loss; profound glycemic normalization
Bremelanotide (PT-141)
Evidence
RECONNECT Trials (n=1,247)
Finding
Statistically significant improvement in HSDD desire scores
Tesamorelin
Evidence
Phase 3 Lipodystrophy Programs (n=806)
Finding
15-18% reduction in visceral adipose tissue (VAT) via MRI